File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: Incidence and molecular monitoring

TitleNonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: Incidence and molecular monitoring
Authors
Issue Date2004
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
Citation
Bone Marrow Transplantation, 2004, v. 34 n. 11, p. 981-985 How to Cite?
AbstractSurvivors of allogeneic hematopoietic stem cell transplantation (HSCT) are at a life-long increased risk of secondary nonhematologic malignancies. In 615 adult Chinese allogeneic HSCT patients, nine developed nonhematologic malignancies. The 5-year cumulative incidence was 6.1%, 4.5 times the background cancer incidence. Early-onset (within first 6 months) and late-onset (>3 years) subtypes were observed. Secondary cancers included hepatocellular carcinoma, oral and esophageal squamous cell tumors and lung adenocarcinoma in a female nonsmoker. The spectrum reflected local cancer epidemiology, which was different from Western populations. The pathogenesis might be related to acceleration of pre-existing cancers (early-onset type), or prolonged immunosuppression (late-onset type). DNA chimerism studies showed that all tumors were recipient-derived. In the plasma, DNA in all cases was apparently donor-derived, although aberrantly methylated p15 was detectable in a patient with a p15-methylated secondary cancer, implying that minute quantities of tumor (and therefore recipient) derived DNA might be present. © 2004 Nature Publishing Group. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/162758
ISSN
2015 Impact Factor: 3.636
2015 SCImago Journal Rankings: 1.585
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorChan, ECen_US
dc.contributor.authorPang, Aen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorYuen, APWen_US
dc.contributor.authorShek, TWHen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:23:07Z-
dc.date.available2012-09-05T05:23:07Z-
dc.date.issued2004en_US
dc.identifier.citationBone Marrow Transplantation, 2004, v. 34 n. 11, p. 981-985en_US
dc.identifier.issn0268-3369en_US
dc.identifier.urihttp://hdl.handle.net/10722/162758-
dc.description.abstractSurvivors of allogeneic hematopoietic stem cell transplantation (HSCT) are at a life-long increased risk of secondary nonhematologic malignancies. In 615 adult Chinese allogeneic HSCT patients, nine developed nonhematologic malignancies. The 5-year cumulative incidence was 6.1%, 4.5 times the background cancer incidence. Early-onset (within first 6 months) and late-onset (>3 years) subtypes were observed. Secondary cancers included hepatocellular carcinoma, oral and esophageal squamous cell tumors and lung adenocarcinoma in a female nonsmoker. The spectrum reflected local cancer epidemiology, which was different from Western populations. The pathogenesis might be related to acceleration of pre-existing cancers (early-onset type), or prolonged immunosuppression (late-onset type). DNA chimerism studies showed that all tumors were recipient-derived. In the plasma, DNA in all cases was apparently donor-derived, although aberrantly methylated p15 was detectable in a patient with a p15-methylated secondary cancer, implying that minute quantities of tumor (and therefore recipient) derived DNA might be present. © 2004 Nature Publishing Group. All rights reserved.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmten_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.subject.meshAdulten_US
dc.subject.meshCarcinoma - Etiology - Geneticsen_US
dc.subject.meshCell Cycle Proteins - Geneticsen_US
dc.subject.meshCyclin-Dependent Kinase Inhibitor P15en_US
dc.subject.meshDna Methylationen_US
dc.subject.meshDna, Neoplasm - Geneticsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHematopoietic Stem Cell Transplantationen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMonitoring, Physiologicen_US
dc.subject.meshNeoplasms, Second Primary - Etiology - Geneticsen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTransplantation Chimera - Geneticsen_US
dc.subject.meshTransplantation Conditioning - Adverse Effectsen_US
dc.subject.meshTumor Suppressor Proteins - Geneticsen_US
dc.titleNonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: Incidence and molecular monitoringen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/sj.bmt.1704674en_US
dc.identifier.pmid15502854-
dc.identifier.scopuseid_2-s2.0-10044247061en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-10044247061&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume34en_US
dc.identifier.issue11en_US
dc.identifier.spage981en_US
dc.identifier.epage985en_US
dc.identifier.isiWOS:000225159800010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridChan, EC=7401994120en_US
dc.identifier.scopusauthoridPang, A=7007044165en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridYuen, APW=7006290111en_US
dc.identifier.scopusauthoridShek, TWH=7005479861en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats